Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
KROS

KROS - Keros Therapeutics Inc Stock Price, Fair Value and News

$17.83-0.47 (-2.57%)
Market Closed

91/100

KROS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

91/100

KROS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$28.8

Target 3M

$23.46

Target 6M

$25.92

KROS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

KROS Price Action

Last 7 days

-6.3%

Last 30 days

-13.6%

Last 90 days

18.6%

Trailing 12 Months

57.7%

KROS RSI Chart

KROS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

KROS Valuation

Market Cap

543.2M

Price/Earnings (Trailing)

8.43

Price/Sales (Trailing)

2.04

EV/EBITDA

-2.07

Price/Free Cashflow

6.24

KROS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$28.8

Target 3M

$23.46

Target 6M

$25.92

KROS Fundamentals

KROS Revenue

Revenue (TTM)

266.7M

Rev. Growth (Yr)

23.88%

Rev. Growth (Qtr)

-21.5%

KROS Earnings

Earnings (TTM)

64.4M

Earnings Growth (Yr)

86.25%

Earnings Growth (Qtr)

76.28%

KROS Profitability

EBT Margin

26.68%

Return on Equity

9.16%

Return on Assets

8.68%

Free Cashflow Yield

16.03%

KROS Investor Care

Buy Backs (1Y)

24.79%

Diluted EPS (TTM)

1.56

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025104.6M185.6M266.7M0
202416.9M19.1M21.3M23.5M
20236.4M9.2M12.0M14.8M
2022014.6M9.1M3.6M
2021013.4M16.7M20.1M
201910.0M10.0M10.0M10.0M
201800010.0M
Get all data in R, Python etc through our Historical Stock Data APIs

About Keros Therapeutics Inc

KROS
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical need in the United States. The company's lead protein therapeutic product candidate KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-047, a small molecule product candidate that is in Phase II clinical trials for the treatment of functional iron deficiency; and KER-012, which is in Phase II clinical trials to treat pulmonary arterial hypertension and cardiovascular disorders. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
 CEO
 WEBSITEkerostx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES121

Keros Therapeutics Inc Frequently Asked Questions

KROS is the stock ticker symbol of Keros Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Keros Therapeutics Inc is 543.21 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check KROS's fair value in chart for subscribers.

The fair value guage provides a quick view whether KROS is over valued or under valued. Whether Keros Therapeutics Inc is cheap or expensive depends on the assumptions which impact Keros Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KROS.

As of Wed Jan 28 2026, KROS's PE ratio (Price to Earnings) is 8.43 and Price to Sales (PS) ratio is 2.04. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KROS PE ratio will change depending on the future growth rate expectations of investors.